OVID vs SGE.L
OVID: A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental epileptic encephalopathies, and psychosis. SGE.L: Sage provides cloud-native financial, HR, and payroll software solutions tailored to the needs of small and medium-sized enterprises globally.
Side-by-side fundamentals
| Metric | OVID | SGE.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $2.80 | £10.86 | |
| Market cap as of 2026-08-24 | $547M | $13.3B | |
| Net margin as of 2026-08-24 | -240.1% | n/a | |
| Operating margin as of 2026-08-24 | -585.2% | n/a | |
| ROE as of 2026-08-24 | -22.5% | n/a | |
| ROA as of 2026-08-24 | -18.7% | n/a | |
| Debt / equity as of 2026-08-24 | 0.00 | n/a | |
| Revenue CAGR (3y) SEC XBRL | +69.0% | n/a | |
| Beta as of 2026-08-24 | 0.26 | n/a | |
| 1-year return as of 2026-08-21 close | +192.6% | -2.5% | OVID higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.